Anti-Aging Pharmacology
- 1st Edition - December 7, 2022
- Editor: Vitaly Koltover
- Language: English
- Paperback ISBN:9 7 8 - 0 - 1 2 - 8 2 3 6 7 9 - 6
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 2 3 6 8 0 - 2
**Association of American Publishers (AAP) PROSE Award Finalist in Clinical Medicine, 2024**Anti-Aging Pharmacology provides an overview of current research aimed at the pharmacolo… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quote**Association of American Publishers (AAP) PROSE Award Finalist in Clinical Medicine, 2024**
Anti-Aging Pharmacology provides an overview of current research aimed at the pharmacological modulation of aging, including a discussion of the growing number of novel drug classes with promising anti-aging potential. The aging process is the main risk factor for all chronic diseases affecting the elderly. With lifespans extending across the globe, these chronic diseases are placing a larger burden on individuals and health care systems. Therefore, slowing down the aging rate could be more effective in delaying aging-associated chronic disorders than combating them one by one, which is the conventional approach in a current disease-based pharmacological paradigm.
This book contains the work of the world’s leading researchers in the field, including sections on the conceptual and methodological background of anti-aging pharmacology, the basic classes of anti-aging drugs, phytochemicals, outcomes of anti-aging developments and future directions. This book will be of interest to a wide audience, ranging from pharmacologists, medicinal chemists and academic researchers in gerontology, biomedical sciences and those in medical practice.
- Includes updated information about current developments in anti-aging pharmacology
- Offers practical advice on the applicability of certain healthspan-promoting medications
- Discusses potential challenges related to the translation of anti-aging drugs in clinical practice
- Cover image
- Title page
- Table of Contents
- Copyright
- Dedication
- Contributors
- Preface
- Acknowledgments
- Chapter 1. Geroscience—the concept
- 1. Introduction
- 2. Geroscience and anti-aging medicine
- 3. Anti-aging pharmacology: state of the art, unresolved issues, and perspectives
- 4. Human health span extension: the longevity dividend
- 5. Could aging be a treatable medical condition?
- 6. Concluding remarks
- Chapter 2. Basic pathways and targets for anti-aging intervention
- 1. Introduction
- 2. Molecular and cellular mechanisms of aging
- 3. Overview of RNA quality control in aging
- 4. Conclusions and future perspectives
- Chapter 3. Omics approaches in aging research
- 1. Introduction
- 2. Life expectancy clocks based on frailty indices
- 3. Epigenomics
- 4. Transcriptomics
- 5. Proteomics
- 6. Metabolomics
- 7. Ionomics
- 8. Cellular senescence
- 9. Gut microbiome
- 10. Conclusions and future perspectives
- Chapter 4. Metformin
- 1. Introduction
- 2. Metformin and health
- 3. Metformin and longevity
- 4. Cause for caution
- 5. Mechanisms of action
- 6. Conclusion
- Chapter 5. Rapamycin and rapalogs
- 1. Inhibition of mTOR signaling extends life span and promotes health span
- 2. The risks of rapamycin
- 3. Why does rapamycin have side effects?
- 4. A simple model: inhibition of mTORC1 is beneficial, inhibition of mTORC2 is detrimental
- 5. Specific targeting of mTORC1 signaling to promote healthy aging
- 6. Conclusion
- Chapter 6. Anti-aging effects of phenolic compounds
- 1. Introduction
- 2. Alzheimer's disease
- 3. Other age-related diseases
- 4. Skin aging
- 5. Conclusions
- Chapter 7. Curcumin
- 1. Introduction
- 2. Phytochemicalsas anti-aging therapeutics: mechanistic considerations
- 3. Curcumin: from chemical structure to therapeutic efficacy
- 4. Curcumin in aging-associated pathology prevention
- 5. Conclusions
- Chapter 8. Pharmacology of NAD+boosters
- 1. Introduction
- 2. Overview of nicotinamide adenine dinucleotide biosynthesis pathways
- 3. Beneficial effects of nicotinamide adenine dinucleotide precursors in disease
- 4. Pharmacokinetics of nicotinamide adenine dinucleotideprecursors
- 5. Conclusions and future perspectives
- Chapter 9. Mitochondrial modulators
- 1. Introduction
- 2. Mitochondria and aging-related signaling pathways
- 3. Mitochondria, telomeres, and aging
- 4. Age-related changes in the mitochondrial genome
- 5. Age-related alteration of mitochondrial permeability
- 6. Mitochondrial dynamics in aging
- 7. Mitochondrial metabolism and caloric restriction
- 8. Mitochondrial metabolism and exercise
- 9. Mitochondria-modulating potential of prolongevity compounds
- 10. Conclusion
- Chapter 10. Nonsteroidal anti-inflammatory drugs
- 1. Introduction
- 2. Nonsteroidal anti-inflammatory drugs and diseases
- 3. Risks of long-term use of aspirin and other nonsteroidal anti-inflammatory drugs
- 4. Conclusions and future directions
- Chapter 11. Senolytics in diseases: killing to survive
- 1. Discovery of cellular senescence
- 2. Senescence in cancer
- 3. Senescence in cardiovascular disease
- 4. Senolytics in metabolic disease
- 5. Senolytics in liver disease
- 6. Senolytics in kidney disease
- 7. Senolytics in lung disease
- 8. Senolytics in neurodegenerative disease
- 9. Senolytics in bone disease
- 10. Senolytics in skin disease
- 11. Conclusion
- Chapter 12. Anti-aging skincare: the natural and organic way
- 1. Introduction
- 2. Current global trends
- 3. The effects of skin aging
- 4. Changes in connective tissues and skin surface pH in aging skin
- 5. Intrinsic and extrinsic aging factors
- 6. Natural and organic skincare
- 7. Natural anti-aging ingredients groups
- 8. Conclusion
- Chapter 13. Protein kinase modulation for anti-aging intervention
- 1. Introduction
- 2. Janus kinase/signal-transducing adapter model signaling pathway
- 3. P70 ribosomal protein S6 kinase
- 4. Hippo signaling pathway
- 5. Mitogen-activated protein kinase signaling pathway
- 6. Conclusions and future perspectives
- Chapter 14. The anti-aging mechanism of Berberine associated with metabolic control
- 1. Introduction
- 2. Mechanisms of berberine in targeting biological metabolic signaling
- 3. The clinical efficacy and side effects of berberine in age-related disease
- 4. Conclusions and future perspectives
- Chapter 15. Growth hormone
- 1. Introduction
- 2. Growth hormone
- 3. Impact of aging on the somatotropic axis
- 4. Physiological meaning of age-related changes in hormone levels
- 5. Effects of growth hormone (GH) administration in GH-deficient vs endocrinolgocially normal adults
- 6. Treatment with growth hormone may affect epigenetic age
- 7. Conclusions
- Chapter 16. Antioxidant pharmacology
- 1. Introduction
- 2. Free-radical hypothesis of aging: prelude
- 3. Free-radical malfunctions in oxidative metabolism
- 4. Free-radical redox-timer of aging in terms of system reliability theory
- 5. Antioxidant therapy: chemical background and experimental findings
- 6. Antioxidant therapy in light of system reliability theory
- Afterword: conclusions and outlook
- Index
- No. of pages: 398
- Language: English
- Edition: 1
- Published: December 7, 2022
- Imprint: Academic Press
- Paperback ISBN: 9780128236796
- eBook ISBN: 9780128236802
VK